Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.65 |
| ▸ | IDO1 | P14902 | 2/20 | 0.57 |
| ▸ | AGXT | P21549 | 2/20 | 0.57 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.52 |
| ▸ | PNMT | P11086 | 1/20 | 0.52 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | NOS1 | P29475 | 2/20 | 0.46 |
| ▸ | NOS2 | P35228 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3401008 | 0.98 | TAAR1 (0.68) | TAAR1IDO1AGXTLOXL2PNMT | |
| SCHEMBL42451 | 0.98 | — | — | |
| SCHEMBL29469769 | 0.98 | — | — | |
| Iodide SCHEMBL28639359 | 0.95 | TAAR1 (0.65) | TAAR1IDO1AGXTLOXL2PNMT | |
| Hydrochloric Acid SCHEMBL302987 | 0.95 | TAAR1 (0.65) | TAAR1IDO1AGXTLOXL2PNMT | |
| Iodide SCHEMBL31162584 | 0.95 | TAAR1 (0.65) | TAAR1IDO1AGXTLOXL2PNMT | |
| SCHEMBL27944031 | 0.84 | TAAR1 (0.53) | TAAR1IDO1AGXTLOXL2PNMT | |
| Bromide SCHEMBL29013587 | 0.82 | LOXL2 (0.67) | TAAR1LOXL2PNMTENPP2NOS1 | |
| Bromide SCHEMBL28362115 | 0.82 | LOXL2 (0.67) | TAAR1LOXL2PNMTENPP2NOS1 | |
| SCHEMBL235748 | 0.79 | TAAR1 (1.00) | TAAR1IDO1AGXTLOXL2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119977906-A | A-site cation-regulated halide perovskite, and preparation method and application thereof | 西北大学 | 2025-05-13 | — | — | CN | disclosed |
| US-9765053-B2 | Methods of treatment using selective 5-HT2A inverse agonists | ACADIA PHARMACEUTICALS INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170165273-A9 | METHODS OF TREATMENT USING SELECTIVE 5-HT2A INVERSE AGONISTS | ANDERSSON CARL-MAGNUS A (DK) | 2017-06-15 | — | — | US | disclosed |
| EP-1787984-B1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | ACADIA PHARM INC (US) | 2016-10-19 | — | — | EP | disclosed |
| US-20160237036-A1 | AZACYCLIC COMPOUNDS | ACADIA PHARM INC (US) | 2016-08-18 | — | — | US | disclosed |
| US-9296694-B2 | Azacyclic compounds | ACADIA PHARMACEUTICALS INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150259291-A1 | AZACYCLIC COMPOUNDS | ACADIA PHARMACEUTICALS INC. | 2015-09-17 | — | — | US | disclosed |
| US-20110301191-A1 | METHODS OF TREATMENT USING SELECTIVE 5-HT2A INVERSE AGONISTS | ANDERSSON CARL-MAGNUS A (DK) | 2011-12-08 | — | — | US | disclosed |
| US-20090186921-A1 | AZACYCLIC COMPOUNDS | ACADIA PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20080051429-A1 | USE OF 4-AMINO-PIPERIDINES FOR TREATING SLEEP DISORDERS | ACADIA PHARMACEUTICALS INC. | 2008-02-28 | — | — | US | disclosed |
| US-20060194778-A1 | Serotonin receptor antagonist; psychological disorders; side effect reduction | ACADIA PHARMACEUTICALS, INC. | 2006-08-31 | — | — | US | disclosed |
| US-20060194834-A1 | Azacyclic compounds | ACADIA PHARMACEUTICALS, INC. | 2006-08-31 | — | — | US | disclosed |
| US-20050014757-A1 | Azacyclic compounds | ANDERSSON CARL-MAGNUS A (DK) | 2005-01-20 | — | — | US | disclosed |
| US-6815458-B2 | NERVOUS SYSTEM DISORDERS | ACADIA PHARMACEUTICALS, INC | 2004-11-09 | — | — | US | disclosed |
| US-6756393-B2 | AMIDES AND UREAS N-SUBSTITUTED WITH PIPERIDINE OR NORTROPANE; SEROTONIN INVERSE AGONISTS OR ANTAGONISTS; ANTIPSYCHOTIC | ACADIA PHARMACEUTICALS, INC. | 2004-06-29 | — | — | US | disclosed |
| US-20030220316-A1 | Azacyclic compounds | ACADIA PHARMACEUTICALS INC. | 2003-11-27 | — | — | US | disclosed |
| CN-1443167-A | Azacyclo compounds for the treatment of 5-hydroxytryptamine related disorders | ACADIA PHARM INC (US) | 2003-09-17 | — | — | CN | disclosed |
| EP-1263729-A1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | Acadia Pharmaceuticals Inc. (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020004513-A1 | Azacyclic compounds | ACADIA PHARMACEUTICALS INC. | 2002-01-10 | — | — | US | disclosed |
| WO-2001066521-A1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | ACADIA PHARMACEUTICALS, INC. (US) | 2001-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259291-A1 | AZACYCLIC COMPOUNDS | HTR6, TPMT, HNMT | TAAR1 62/4885IDO1 512/4885AGXT 3235/4885 |
| US-20110301191-A1 | METHODS OF TREATMENT USING SELECTIVE 5-HT2A INVERSE AGONISTS | HTR2A, HTR5A, HTR3B | TAAR1 110/4885IDO1 838/4885AGXT 2942/4885 |
| US-20060194834-A1 | Azacyclic compounds | HTR6, HTR5A, HNMT | TAAR1 61/4885IDO1 688/4885AGXT 3792/4885 |
| US-20090186921-A1 | AZACYCLIC COMPOUNDS | HTR6, HTR5A, HNMT | TAAR1 61/4885IDO1 688/4885AGXT 3792/4885 |
| US-20030220316-A1 | Azacyclic compounds | HTR6, TPMT, HNMT | TAAR1 62/4885IDO1 512/4885AGXT 3235/4885 |
| US-20020004513-A1 | Azacyclic compounds | HTR6, TPMT, HNMT | TAAR1 62/4885IDO1 512/4885AGXT 3235/4885 |
| US-20080051429-A1 | USE OF 4-AMINO-PIPERIDINES FOR TREATING SLEEP DISORDERS | HTR4, HTR3B, HTR2A | TAAR1 122/4885IDO1 785/4885AGXT 4486/4885 |
| US-20050014757-A1 | Azacyclic compounds | HTR6, TPMT, HNMT | TAAR1 62/4885IDO1 512/4885AGXT 3235/4885 |
| US-20170165273-A9 | METHODS OF TREATMENT USING SELECTIVE 5-HT2A INVERSE AGONISTS | HTR2A, HTR5A, HTR3B | TAAR1 110/4885IDO1 838/4885AGXT 2942/4885 |
| US-20160237036-A1 | AZACYCLIC COMPOUNDS | HTR6, TPMT, HNMT | TAAR1 62/4885IDO1 512/4885AGXT 3235/4885 |
| US-20060194778-A1 | Serotonin receptor antagonist; psychological disorders; side effect reduction | HTR2A, HTR1A, HTR1B | TAAR1 40/4885IDO1 899/4885AGXT 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.